Literature DB >> 8710059

Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.

I Litvan1, Y Agid, D Calne, G Campbell, B Dubois, R C Duvoisin, C G Goetz, L I Golbe, J Grafman, J H Growdon, M Hallett, J Jankovic, N P Quinn, E Tolosa, D S Zee.   

Abstract

To improve the specificity and sensitivity of the clinical diagnosis of progressive supranuclear palsy (PSP, Steele-Richardson-Olszewski syndrome), the National Institute of Neurological Disorders and Stroke (NINDS) and the Society for PSP, Inc. (SPSP) sponsored an international workshop to develop an accurate and universally accepted set of criteria for this disorder. The NINDS-SPSP criteria, which were formulated from an extensive review of the literature, comparison with other previously published sets of criteria, and the consensus of experts, were validated on a clinical data set from autopsy-confirmed cases of PSP. The criteria specify three degrees of diagnostic certainty: possible PSP, probable PSP, and definite PSP. Possible PSP requires the presence of a gradually progressive disorder with onset at age 40 or later, either vertical supranuclear gaze palsy or both slowing of vertical saccades and prominent postural instability with falls in the first year of onset, as well as no evidence of other diseases that could explain these features. Probable PSP requires vertical supranuclear gaze palsy, prominent postural instability, and falls in the first year of onset, as well as the other features of possible PSP. Definite PSP requires a history of probable or possible PSP and histopathologic evidence of typical PSP. Criteria that support the diagnosis of PSP, and that exclude diseases often confused with PSP, are presented. The criteria for probable PSP are highly specific, making them suitable for therapeutic, analytic epidemiologic, and biologic studies, but not very sensitive. The criteria for possible PSP are substantially sensitive, making them suitable for descriptive epidemiologic studies, but less specific. An appendix provides guidelines for diagnosing and monitoring clinical disability in PSP.

Entities:  

Mesh:

Year:  1996        PMID: 8710059     DOI: 10.1212/wnl.47.1.1

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  717 in total

Review 1.  Progressive supranuclear palsy.

Authors:  H U Rehman
Journal:  Postgrad Med J       Date:  2000-06       Impact factor: 2.401

Review 2.  Progressive supranuclear palsy (Steele-Richardson-Olszewski disease).

Authors:  H R Morris; N W Wood; A J Lees
Journal:  Postgrad Med J       Date:  1999-10       Impact factor: 2.401

3.  Magnetization transfer measurements of the hippocampus in patients with Alzheimer's disease, vascular dementia, and other types of dementia.

Authors:  H Hanyu; T Asano; T Iwamoto; M Takasaki; H Shindo; K Abe
Journal:  AJNR Am J Neuroradiol       Date:  2000-08       Impact factor: 3.825

4.  In vivo evaluation of white matter pathology in patients of progressive supranuclear palsy using TBSS.

Authors:  Jitender Saini; Bhavani Shankara Bagepally; Mangalore Sandhya; Shaik Afsar Pasha; Ravi Yadav; Pramod Kumar Pal
Journal:  Neuroradiology       Date:  2011-12-09       Impact factor: 2.804

5.  Reversible progressive supranuclear palsy-like phenotype as an initial manifestation of HIV infection.

Authors:  Wooyoung Jang; Joong-Seok Kim; Jin Young Ahn; Hee-Tae Kim
Journal:  Neurol Sci       Date:  2011-12-09       Impact factor: 3.307

6.  Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials.

Authors:  Jennifer L Whitwell; Jia Xu; Jay N Mandrekar; Jeffrey L Gunter; Clifford R Jack; Keith A Josephs
Journal:  Parkinsonism Relat Disord       Date:  2011-11-13       Impact factor: 4.891

7.  Greater Experience of Negative Non-Target Emotions by Patients with Neurodegenerative Diseases Is Related to Lower Emotional Well-Being in Caregivers.

Authors:  Kuan-Hua Chen; Jenna L Wells; Marcela C Otero; Sandy J Lwi; Claudia M Haase; Robert W Levenson
Journal:  Dement Geriatr Cogn Disord       Date:  2017-12-08       Impact factor: 2.959

8.  Accuracy of death certificates for recording parkinsonian syndromes and associated dementia.

Authors:  Hanxu Shi; Carl Counsell
Journal:  J Neurol       Date:  2020-07-31       Impact factor: 4.849

Review 9.  Tauopathies as clinicopathological entities.

Authors:  David J Irwin
Journal:  Parkinsonism Relat Disord       Date:  2015-09-08       Impact factor: 4.891

Review 10.  The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases.

Authors:  Filippo Baldacci; Sonia Mazzucchi; Alessandra Della Vecchia; Linda Giampietri; Nicola Giannini; Maya Koronyo-Hamaoui; Roberto Ceravolo; Gabriele Siciliano; Ubaldo Bonuccelli; Fanny M Elahi; Andrea Vergallo; Simone Lista; Filippo Sean Giorgi; Harald Hampel
Journal:  Expert Rev Mol Diagn       Date:  2020-02-27       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.